Shearman And Sterling

News September 30, 2015

Shearman & Sterling Advises MedeAnalytics on Sale of Majority Stake to Thoma Bravo

Shearman & Sterling advised MedeAnalytics, Inc., a provider of cloud-based financial performance analytics for the healthcare industry, on its sale of a majority stake to Thoma Bravo, LLC, a leading private equity investment firm. Prior investors Bain Capital Ventures and Emergence Capital Partners will remain minority shareholders. Financial details were not disclosed.

MedeAnalytics provides evidence-based insights that help healthcare providers leverage the vast amounts of data available to deliver cost-effective care and promote a healthier population. Through its analytics platform, MedeAnalytics delivers the intelligence that healthcare organizations require to improve their financial health. MedeAnalytics’ cloud-based tools are used by over 1500 healthcare organizations globally. Analytics have played an important and growing role in the healthcare industry, as reigning in costs and providing faster payment turnaround times for insurers and providers is essential to their success.

Thoma Bravo is a leading private equity investment firm building on a 30+ year history of providing equity and strategic support to experienced management teams and growing companies. The firm seeks to create value by collaborating with company management to improve business operations and provide capital to support growth initiatives. Thoma Bravo invests with a particular focus on application and infrastructure software and technology enabled services. The firm currently manages a series of private equity funds representing more than $8.5 billion of equity commitments.

The Shearman & Sterling team included partners Rob Masella (New York-Mergers & Acquisitions), counsel Sean Skiffington (Toronto-Mergers & Acquisitions), and associates Aselle Kurmanova (New York-Mergers & Acquisitions), Michael Dockery (New York-Mergers & Acquisitions), Joanna Enns (Toronto-Corporate) and Zach Shub-Essig (New York-Mergers & Acquisitions). Also advising MedeAnalytics in the transaction were partners Larry Crouch, Alan Goudiss, Richard Hsu, and Doreen Lilienfeld; counsel Daniel Stellenberg; and associates Benjamin Petersen, Kelly Karapetyan, Francisco Cebada, Mark Langer, Mark Pereira and Kyle Phillips.